Instead of the traditional 'disease-target-drug' approach, Soleil finds compounds that create a desired cellular change first. Only after identifying a promising, well-tolerated molecule with a known cellular mechanism do they use bioinformatics to determine which disease and patient population it's best suited for.

Instead of targeting individual gene mutations in diseases like ALS, condensate science focuses on shared cellular structures where genetic risks converge. This approach creates a broader therapeutic target, potentially treating more patients with diverse genetic profiles.

Instead of creating therapies for hundreds of specific driver mutations, which vary widely between patients, Earli's platform targets downstream commonalities—the "hallmarks of cancer" like rapid cell proliferation. These pathways are where diverse mutations converge, creating a more universal and reliable target across different cancers.

Traditional targeted cancer therapies inhibit or 'cool down' overactive pathways, like pumping brakes on a runaway car. Delpha Therapeutics employs a counterintuitive 'activation lethality' approach, further over-activating pathways to 'overheat the engine' and cause catastrophic failure in cancer cells—a fundamentally opposite but highly effective strategy.

By focusing on the phenotypic outcome (cellular stress) rather than a predefined target, Soleil's platform can identify small molecules that modulate proteins considered undruggable by conventional means. Their lead oncology candidate, for example, modulates CCAP2, demonstrating the platform's ability to find novel biology and expand the druggable space.

Coya's therapeutic approach is not limited to ALS. The company views the underlying mechanism—dysfunctional regulatory T-cells driving neuroinflammation—as a common pathway in other conditions like frontotemporal dementia, Alzheimer's, and Parkinson's. This positions their drug as a platform technology, creating a broader pipeline and de-risking the company from reliance on a single indication.

BioAge is framing its oral drug BGE-102 as a single asset that can address inflammation across cardiovascular, ocular, and CNS diseases. This "pipeline in a pill" strategy transforms a single molecule into a broad platform by targeting a fundamental aging mechanism that cuts across many tissues and conditions.

The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.

All therapeutic discoveries fall into two types. The first is a biological insight, where the challenge is to find a way to drug it. The second is a technical advancement, like a new platform technology, where the challenge is to find the right clinical application for it. This clarifies a startup's core problem.